Does GHK-Cu have FDA product approval?

No. GHK-Cu is not FDA-approved, including the compounded formulation offered here. The pending FDA process concerns whether an ingredient belongs on the 503A compounding list. Even a favorable committee recommendation would be advice to the agency, not approval of a finished medicine or proof of a benefit for a particular patient.

Is GHK-Cu still in Category 2?

Injectable GHK-Cu appears among withdrawn nominations rather than in FDA's current Category 2 table. Non-injectable GHK-Cu is listed separately in Category 1, meaning under evaluation, in the document updated May 14, 2026. That distinction matters: a status statement about a cream cannot automatically be applied to an injection.

When will the FDA committee review GHK-Cu?

FDA says before the end of February 2027; its meeting page had no specific day or time as of September 10, 2026. The five-substance agenda includes GHK-Cu. The July 23–24, 2026 meeting concerned seven other peptides, so those proceedings did not settle the GHK-Cu question.

Does research on GHK-Cu creams establish injection safety?

No. Skin applications and injections expose the body differently, so evidence from one cannot establish safety for the other. Published human work includes wound gels and skin care after laser treatment. FDA separately identifies limited human safety information and possible immune-response concerns for compounded injectable GHK-Cu.

Does a review of one KLOW ingredient settle the whole blend?

No. KLOW combines GHK-Cu, BPC-157, TB-500 and KPV in one preparation, and evidence about an ingredient does not establish the effects of the complete blend. The committee's separate consideration of individual ingredients cannot replace a clinical assessment of the formulation, route and person for whom it is being considered.

Is GHK-Cu FDA Approved? No, Its Review Is Pending

The answer is no to “is GHK-Cu FDA approved?” The compounded formulation offered here is not FDA-approved. FDA's pending review concerns whether pharmacies can use GHK-Cu as a starting ingredient. It is not a review of a finished medicine for sale.

The history makes more sense once one detail is clear: FDA has treated GHK-Cu applied without an injection differently from GHK-Cu injected into the body.

How GHK-Cu entered the compounding review

GHK-Cu is a peptide, a short chain of building blocks called amino acids, attached to copper. Its nomination asked FDA to consider it for the 503A bulks list: the list of starting ingredients that can qualify for use in medicines prepared for individual prescriptions under federal conditions.

By September 29, 2023, FDA had received enough supporting information to evaluate non-injectable GHK-Cu. Its document marked “Updated September 29, 2023” placed that use in Category 1, meaning under evaluation. The same update placed injectable GHK-Cu in Category 2, the group for ingredients with identified safety concerns. Those were different entries from the start. (FDA's September 2023 update, preserved by the Alliance for Pharmacy Compounding)

What the Category 2 concern meant

FDA's concern was about the injected preparation. The agency describes immunogenicity, meaning an unwanted immune response, associated with possible peptide clumping and impurities. It also identifies limited human safety data. Its published safety explanation retains those points under withdrawn nominations.

That is a specific evidence gap. It doesn't give a percentage of people who will have a reaction, and it doesn't establish that every formulation produces one. It explains why the pharmacy's preparation and the way the medicine enters the body matter alongside the ingredient's name.

Promise's GHK-Cu offering is an injectable compounded medication, meaning a pharmacy prepares it for a prescription. That route distinction therefore matters to the visit: a statement about non-injectable GHK-Cu cannot describe the vial by default.

April and May 2026: withdrawal, then a clarification

As of September 10, 2026, the day this article was written, FDA's current nominations document carries the date “Updated May 14, 2026.” It records that non-injectable GHK-Cu was removed from Category 1 on April 22 after nominations were withdrawn. On May 5, one nominator clarified that only its injectable nomination was meant to be withdrawn, so the non-injectable entry returned to Category 1.

Injectable GHK-Cu remains in the separate withdrawn-nominations table on FDA's safety page. It is not in the current Category 2 table, and it did not inherit the non-injectable entry's Category 1 status.

The second meeting is the one that includes GHK-Cu

The April announcement involved separate proceedings. Federal Register notice 2026-07361 was filed April 15 and published April 16, 2026. It set the July 23–24 meeting for seven other peptides; GHK-Cu was absent from that agenda. (The complete Federal Register notice)

As of September 10, 2026, the day this article was written, FDA's GHK-Cu meeting page still says the meeting will happen before the end of February 2027, without a specific day or time. Its five-substance agenda names GHK-Cu, cathelicidin (LL-37), Dihexa acetate, Melanotan II and PEG-MGF. These are agenda entries, not treatment recommendations.

The Pharmacy Compounding Advisory Committee, or PCAC, is the outside expert panel that advises FDA. July's separate proceeding is covered in the FDA peptide decision explained; its recommendations do not decide GHK-Cu's review.

This matters for blends, too. KLOW contains GHK-Cu alongside BPC-157, TB-500 and KPV. A discussion of those other ingredients cannot settle the status or clinical evidence of the whole four-ingredient preparation. The provider considers the actual blend being requested.

What an FDA staff review would weigh

The FDA briefing introduction dated July 23–24, 2026 gives the framework for ingredient reviews. It is a useful template, not a GHK-Cu finding. FDA weighs four questions together:

Identity and chemistry: Can the ingredient be reliably identified and its quality described?
Safety: What unwanted effects or unanswered safety questions arise in compounded preparations?
Effectiveness: What evidence supports the particular use, and what evidence fails to support it?
History: How has the ingredient actually been used in compounded medicines?

Published human work shows why those questions need a specific route and purpose. A randomized study, which assigned treatments by chance, tested GHK-Cu gel on diabetic foot wounds alongside organized wound care. This was human medical research beyond cosmetic facial studies, but it still tested application to a wound, not injections. (Mulder and colleagues, Wound Repair and Regeneration, 1994)

In a different trial after laser skin treatment, 13 people completed the study. Patient satisfaction favored GHK-Cu skin care, while independent assessments found no significant advantage in redness, wrinkles or overall skin quality. Both findings belong in the evidence. (Miller and colleagues, Archives of Facial Plastic Surgery, 2006)

As of September 10, 2026, the day this article was written, a new Aesthetic Surgery Journal review, published August 20 and marked “Corrected and typeset” September 5, counts 20 eligible aesthetic studies. Eighteen were preclinical, meaning cell or animal work, and two were randomized human trials. That count concerns aesthetic uses, not every medical use ever studied; the GHK-Cu clinical evidence guide examines that review further.

Is GHK-Cu FDA approved? The answer remains no

A committee vote cannot grant product approval. Its recommendation goes to FDA, which considers it with the evidence. Changes to the ingredient list proceed through rulemaking: a published proposal, public comments and a final regulation. FDA describes that process on its 503A ingredient-list page.

As of September 10, 2026, the day this article was written, the GHK-Cu consultation remains pending. The next useful records are its dated meeting notice, the staff assessment and eventually the agency's action. A future ingredient-list entry would still not make compounded GHK-Cu FDA-approved.

A licensed provider may still prescribe a compounded formulation when clinically appropriate; that decision is between the patient and the doctor. Prescribing judgment and the pharmacy's dispensing requirements both matter. Neither a prescription nor a committee recommendation replaces the other requirements.

What belongs in the visit now

The practical conversation concerns the preparation being considered, the reason for using it, medical history and what follow-up can measure. GHK-Cu side effects by route covers the safety questions in more detail.

At Promise, a licensed provider reviews every request and not everyone qualifies. The visit gives the patient someone accountable for that decision and for reassessing it as evidence changes. A future meeting date cannot do that work for an individual person.